99 results about "Prolonged-release tablet" patented technology

The invention relates to the technical field of oral non-biological medicine preparations, in particular to an upatinib sustained release tablet and a preparation method thereof. The invention discloses a preparation method of an upatinib sustained-release tablet, and aims to solve the problem that the dissolution rate of the upatinib sustained-release tablet is unstable, namely, the upatinib sustained-release tablet can stably control the release of upatinib in different gastrointestinal tract environments through the synergistic cooperation of all the components of the upatinib sustained-release tablet, and the preparation method of the upatinib sustained-release tablet is relatively low in cost and easy to operate. The large-scale production is facilitated; the upatinib sustained release tablet comprises the following components in percentage by weight: 3.0%-3.5% of upatinib, 18%-19.50% of a pH regulator, 50%-55% of a filler, 17%-22% of an adhesive, 0.1%-1% of a flow aid, 1%-2% of a lubricant and 0.01%-10.9% of a coating material.

The application discloses a salbutamol sulfate sustained-release tablet and a preparation process thereof. The preparation process comprises the following steps: drug micronization treatment, drug and ion exchange resin compounding, granulation with hydrophilic gel matrix material, gradient temperature control drying, total mixing after whole granulation, tabletting, double controlled-release coating, ladder solidification treatment and screening and packaging. Through the synergistic sustained-release effect of the ion exchange resin and the hydrophilic gel matrix material, the double controlled-release coating and the ladder solidification process, the application effectively inhibits drug burst release, realizes smooth and long-lasting release, reduces impurity content, and improves product stability and batch reproducibility. The obtained sustained-release tablet releases 20%-40% in 2 hours and 80% or more in 8 hours in a pH 6.8 phosphate buffer, and the quality is controllable, so the sustained-release tablet is suitable for industrial production.

The utility model discloses a tablet press feed hopper for sustained release tablet production, which relates to the technical field of sustained release tablet production and comprises a feed hopper, a mounting seat is arranged at the bottom of the feed hopper, a connecting top cover is arranged at the top of the feed hopper, a connecting sleeve is arranged at the bottom of the connecting top cover, and a positioning bolt is arranged outside the connecting sleeve. An anti-blocking assembly is arranged on the top of the connecting top cover, a pulling handle is installed on one side of the top of the connecting top cover, and the pulling handle and the anti-blocking assembly are arranged adjacently. Raw materials accumulated in the feeding hopper are conveyed through the arranged anti-blocking assembly, the rotating rod and the spiral conveying paddle are driven by the arranged driving motor to rotate, so that the raw materials are conveyed, and meanwhile the raw materials are prevented from being accumulated in the feeding hopper, blocking is caused, and the discharging efficiency is affected; the spiral conveying paddle is used in cooperation with the cleaning scraping plate, and the raw material station is prevented from adhering to the inner wall of the feeding hopper.

This application relates to the field of pharmaceutical equipment technology, and discloses an apparatus and method for granulating sustained-release drugs, to solve the problem of rapid drug release from sustained-release tablets due to short compression time and lack of compaction. A granulation structure is fixedly installed inside a housing. The granulation structure includes a fixed plate, a support shaft, a rotating gear, and a granulation belt. The granulation belt has a granulation groove, and two granulation belts are installed in a V-shape. Powdered sustained-release drug is discharged into the granulation groove. A power motor drives the support shaft, rotating gear, and granulation belt to rotate in opposite directions, causing the granulation groove to compress the powdered sustained-release drug in the granulation groove. As the granulation groove moves from the top to the bottom of the granulation belt, the compressive force on the powdered sustained-release drug increases, and the compression time of the powdered sustained-release drug in the granulation groove is extended, so that the powdered sustained-release drug is compacted, preventing breakage of the compressed sustained-release tablets.

The invention discloses a centrifugal granulation process for producing slow-release indapamide, which comprises the following steps: S1, stirring and mixing indapamide, a slow-release framework material, a lubricant and a filler; s2, putting the mixed powder into a disc of a granulation device, and performing low-speed centrifugal granulation in a vacuum state to form a mother nucleus; s3, transferring the mother nucleus to a high-pressure state for centrifugal granulation; s4, performing low-temperature drying on the granules; and S5, after drying, tabletting by using a tablet press, and finally coating and packaging by using double aluminum to obtain the indapamide sustained-release tablet. According to the invention, high and low pressure conversion is carried out in the centrifugal granulation process, so that gas in the sustained-release tablet is reduced, the density is increased synchronously, and the sustained-release capability and the efficacy durability of the tablet are improved.

A modified-release tablet dosage form containing tolcapone is disclosed. The tablet dosage form provides a pulsatile, pH-dependent release profile of tolcapone to both the gastric cavity and the small intestine. Methods for treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's disease, and obsessive-compulsive disorder using the dosage form are provided.

The invention discloses an ingredient mixing device and method for sodium valproate sustained release tablet production, and relates to the field of pharmaceutical equipment.The ingredient mixing device comprises a mixing main body, the top of the mixing main body is connected with a top cover through a plurality of bolts, the bottom of the top cover penetrates through the bottom and is fixedly connected with a feeding cylinder, and a main shaft is arranged in the center of the interior of the mixing main body; four outer plates are fixedly connected to the outer surface of the main shaft at equal intervals, and a mixed discharging switching structure is arranged in the mixing main body. By arranging the mixing and discharging switching structure, rapid switching between a mixing mode and a discharging mode is achieved, and the structure allows a channel to be opened in the mixing stage so that materials can be subjected to sufficient convection, and allows the channel to be closed in the discharging stage so that the materials can be guided to an outlet; due to the integrated design, the tedious step that materials need to be transferred to another device for discharging after mixing in a traditional technology is avoided, the risks of procedure interruption, material loss and cross contamination are remarkably reduced, and the continuity and the overall efficiency of the production process are greatly improved.

The utility model discloses a kind of layered compression devices of multilayer sustained-release tablet, belong to pharmaceutical equipment technical field.This kind of layered compression device of multilayer sustained-release tablet, including processing table, the bottom end of processing table is equipped with support frame, the top end middle part of processing table is rotatably connected with pivot, the top end of pivot is equipped with carousel, the top end outside of carousel is equipped with several compression grooves, the inside bottom end of compression groove is equipped with ejection plate, the bottom end of pivot is through the bottom end of processing table, the bottom end of processing table is equipped with adjusting mechanism for rotating pivot, the top end of carousel is equipped with pusher mechanism, the bottom end side of processing table is equipped with first electric telescopic rod, the top end of processing table is through the output of first electric telescopic rod, the output of first electric telescopic rod and the bottom end of ejection plate are contacted, the side of processing table is equipped with stand, the side top end of stand is equipped with horizontal plate, the utility model can effectively realize automatic discharge function, improve discharging efficiency, with higher practical value.

The invention discloses a doxazosin mesylate sustained-release tablet and a preparation process thereof, and relates to the technical field of doxazosin mesylate sustained-release tablets.The sustained-release tablet comprises a double-layer tablet core composed of a first sustained-release layer and a second sustained-release layer; the double-layer tablet core is prepared from the following components in parts by mass: a first slow-release layer and a second slow-release layer; the first slow-release layer is prepared from the following components in parts by mass: 2.4 parts of chitosan-TPP modified doxazosin mesylate, 10 to 12.5 parts of citric acid-cassava starch, 12.5 to 15 parts of magnesium aluminum silicate-cassava starch, 40 to 60 parts of microcrystalline cellulose and 3 to 4 parts of magnesium stearate; the second slow-release layer is prepared from the following components in parts by weight: 2.4 parts of chitosan-TPP modified doxazosin mesylate, 1.44 to 3.36 parts of carrageenan, 130 to 140 parts of polyethylene oxide, 30 to 40 parts of sodium alginate, 55 to 65 parts of citric acid, 67 to 77 parts of microcrystalline cellulose and 3 to 4 parts of magnesium stearate.

The fragrance filter element comprises a filter element body and fragrance materials filled in the filter element body, the filter element body comprises a fragrance bottle, a filter element ring and a fairing, the filter element ring is arranged between the fragrance bottle and the fairing in a sleeved mode, the fairing is arranged on the upper portion of the fragrance bottle, and a rectification mixing cavity is formed between the inner wall of the fairing and the outer wall of the fragrance bottle. A slow release hole is formed in the top end of the fragrance bottle to communicate the rectification mixing cavity with a fragrance bottle cavity in the rectification mixing cavity, a fragrance material is placed in the fragrance bottle, and a rectification water outlet hole is formed in the rectification cover; an upper sustained-release tablet is arranged in the fragrance bottle, and an anti-overflow cavity is formed between the upper sustained-release tablet and the sustained-release hole; water enters the rectification mixing cavity from the filter element ring, the fragrance material in the fragrance bottle cavity is gradually dissolved through the slow release holes, and then the fragrance material is mixed into water and flows out through the rectification water outlet hole. The fragrance filter element is installed in the shower head in a replaceable mode, water in the shower head cannot directly enter the interior of the fragrance filter element from the bottom of the fragrance filter element to impact and dissolve the fragrance material, the fragrance material can be dissolved in the water permanently and stably, and a user can use the fragrance filter element conveniently.

This invention relates to an utpatinib sustained-release tablet and its preparation method, belonging to the field of pharmaceutical formulation technology. The sustained-release tablet comprises a core and a coating layer. The core is formed by mixing and pressing drug-containing sustained-release particles with excipients. The drug-containing sustained-release particles are prepared by wet granulation and drying of utpatinib hemihydrate, hydroxypropyl methylcellulose, and small-particle-size microcrystalline cellulose, with the residual moisture content of the particles controlled at 1.0%–3.0% (w / w). The excipients include anhydrous citric acid, large-particle-size microcrystalline cellulose, lubricant, flow aid, and mannitol. This invention effectively solves the problems of utpatinib solubility being greatly affected by pH, unstable release, and easy tablet cracking under high hardness by constructing a synergistic system of pH adjustment and gel density, and by utilizing anhydrous citric acid to create an acidic microenvironment and enhance the strength of the HPMC gel layer, combined with the internal and external division of labor between small-particle-size and large-particle-size microcrystalline cellulose.

The invention belongs to the field of medicine cutting devices, and discloses a western medicine sustained release tablet cutting and positioning device which comprises a positioning pipe and a cutting pipe, the cutting pipe is slidably connected with a connecting shaft, the connecting shaft is connected with a connecting plate and a pressing part, the connecting plate and the inner wall of the cutting pipe are jointly connected with a second spring, the connecting plate is connected with a cutter, and the cutter is connected with a second spring. A clamping plate is rotatably connected to the inner wall of the positioning pipe, a sliding rod is connected to the inner wall of the positioning pipe, a sliding ring is slidably connected to the sliding rod, the clamping plate and the sliding ring are jointly and rotatably connected with a rotating rod, the sliding rod is sleeved with a first spring, and a medicine containing protruding block is connected to the inner wall of the positioning pipe. According to the scheme, through a flexible self-adaptive clamping and buffering segmentation structure, fragmentation is effectively prevented while tablets are segmented, immediate separation of fragments is achieved, and the accuracy and integrity of the dosage of the sustained release tablets are guaranteed.

The application discloses a quetiapine fumarate sustained-release tablet and a preparation method thereof. The sustained-release tablet is a multilayer sustained-release tablet prepared by layering and compressing after loading quetiapine fumarate in a hydrogel made of chitosan and carboxymethyl cellulose and drying. The sustained-release tablet comprises an outer layer, a middle layer and an inner layer, and the densities of the outer layer, the middle layer and the inner layer are sequentially reduced. The sustained-release tablet comprises the following components in parts by weight: quetiapine fumarate, chitosan, carboxymethyl cellulose, nano-silicon dioxide, lactose, microcrystalline cellulose and a lubricant. The components are prepared into the sustained-release tablet with excellent sustained-release effect through solution preparation, multiple cross-linking, layering and compressing and the like. The release time of the sustained-release tablet can reach 24 hours, the burst release condition at the initial stage of release is significantly reduced, the release in the first four hours is not more than 20%, the overall release effect is relatively stable, the drug absorption is facilitated, and the effect of once-a-day administration or longer time interval administration can be achieved.

The invention relates to the technical field of screening of effective components of traditional Chinese medicine compound preparations, and discloses a deep learning-based method for screening effective parts of compound mengbrand colon sustained-release tablets, which comprises the following steps of: constructing a time sequence pharmacodynamic pathway library, and recording biological pathway activity data of each component of the compound mengbrand colon sustained-release tablets at a plurality of time points; designing a causal intervention traceability network, and analyzing and quantifying the causal relationship of each component to a path node through anti-factual intervention; developing a key node identification algorithm, and identifying key regulation and control nodes; establishing a pathway evolution tracking model, and predicting the long-term influence of the drug components on the pathway; generating a mechanism interpretability score, and evaluating the pharmacodynamic mechanism reliability of each component; effective components with a definite action mechanism are screened out; according to the method, by constructing the time sequence pharmacodynamic pathway library, the complete change process of the biological pathway at multiple time points after drug intervention can be recorded, and the limitation that a traditional static end point observation method cannot track a complete causal chain is overcome.

The invention discloses a Vilciguat sustained-release tablet which comprises the following raw materials: Vilciguat particles and a sustained-release material, and the Vilciguat particles are obtained by granulating a Vilciguat aqueous solution with the pH value of 2-6 and a filler. The invention also discloses a preparation method of the Vilciguat sustained-release tablet, which comprises the following steps: uniformly mixing the raw materials of the Vilciguat sustained-release tablet, granulating, and tabletting to obtain the Vilciguat sustained-release tablet. According to the invention, through mutual cooperation of the raw materials and a specific process, the influence of intestinal environment and diet on dissolution and efficacy of the viriciguat can be avoided, the problems of repeated dissolution, precipitation and re-dissolution of the viriciguat in intestinal tracts are avoided, the dissolution effect is improved, and the viriciguat can play a more stable and longer curative effect; in addition, through mutual cooperation of the raw materials and a specific process, the Velciguat sustained release tablet has good stability.

The invention relates to a B-vitamin sports nutrition sustained release tablet and a preparation method thereof. The sustained release tablet comprises B vitamins, a lipid phase forming agent, a natural deep eutectic system glass precursor, a water activity buffer pair, ion exchange resin particles and conventional auxiliary materials, the preparation method comprises the following steps: preparing a natural deep eutectic system glass precursor, dissolving and loading the vitamin B, preparing a lipid semi-solid phase, carrying out dry mixing and wet kneading granulation, carrying out low-temperature drying granulation, carrying out final mixing, adding ion exchange resin particles subjected to standing exchange with the vitamin B and a lubricant, and tabletting. The sustained release tablet is used for sports crowds or crowds with B-group vitamin supplement requirements, and has the advantages of being strong in B-group vitamin stability protection effect in the storage and use process and capable of achieving gradual release in the gastrointestinal tract environment; the preparation method disclosed by the invention does not need a complicated microcapsule or core-shell coating process, and a slow-release effect can be realized by utilizing conventional tablet equipment.

The invention relates to the technical field of medicines, in particular to a dihydroergoline mesylate sustained-release tablet containing an antioxidant synergistic system and a preparation method of the dihydroergoline mesylate sustained-release tablet. The preparation method comprises the following steps: firstly, preparing double-molecular-weight polyethylene glycol composite microspheres as a pore-foaming agent; preparing antioxidant regulation particles, forming a buffer microenvironment by tartaric acid, citric acid monohydrate, sodium citrate and the like, and adding a water-soluble antioxidant; then preparing a fat-phase antioxidant skeleton mixture, and loading a fat-soluble antioxidant; preparing drug-containing core particles from dihydroergoline mesylate and a part of the skeleton mixture; and after mixing and tabletting, sequentially carrying out bottom layer hydrophilic film coating, middle powder layer coating and outer layer functional film coating. The sustained release tablet is stable in release within 24 hours and good in batch-to-batch consistency, oxidation impurities in acceleration and long-term stability tests are remarkably reduced, and the medication safety and the long-term effect are effectively guaranteed.

The present application relates to a kind of upatin sustained-release tablets and preparation method thereof.The present application uses mannitol, microcrystalline cellulose as filler, hydroxypropyl methyl cellulose as matrix material, malic acid as pH regulator, colloidal silicon dioxide as glidant, magnesium stearate as lubricant, after mixing raw drug with one or more excipients, dry granulation, solve the upatin preparation in the tabletting process due to the hygroscopicity of pH regulator and cause the problem of astringent, sticky and product quality change, shorten the drying time of moisture control in coating process, tablet is more stable in the process of acceleration test and influencing factor test.

The application discloses a coating composition of nifedipine sustained-release tablets, a preparation method and a coating process. The composition comprises HPC-L, HPC-M, polydopamine, PVP K30 and hydrophilic nanosilica, and can improve the hydration coordination of the coating layer, the film stability and the sustained-release stability.

This invention relates to the field of pharmaceutical technology, specifically to a sustained-release tablet of dihydroergot mesylate with composite network regulation and its preparation method. The sustained-release tablet comprises a composite structure consisting of a drug-resin composite core, an inner interface regulation structure, and an outer composite network. The key to its preparation lies in: forming a wet complex of dihydroergot mesylate with a strongly acidic cation exchange resin; sequentially introducing low-viscosity hydroxypropyl methylcellulose and a first portion of ethyl cellulose to construct the inner interface regulation layer; and after semi-drying, adding high-viscosity hydroxypropyl methylcellulose and a second portion of ethyl cellulose to form the outer composite network framework. This structure can significantly inhibit the burst release of the drug in gastric juice and achieve a stable and sustained release in intestinal juice, with stable tablet quality and good industrialization prospects.

1. Name of the product in this design: Pharmaceutical Packaging Box (Pariporone Extended-Release Tablets). 2. Purpose of this design: Packaging box for paliperidone sustained-release tablets. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the key design points: Design 1 3D view. 5. The design for which protection is sought includes color. 6. Design 1 is designated as the basic design.

The application belongs to the technical field of direct compression of pharmaceutical preparations, and particularly relates to a sustained-release isosorbide mononitrate tablet and a preparation method thereof. The sustained-release tablet is composed of a sustained-release tablet core and a coating layer. After isosorbide mononitrate, hydroxypropyl cellulose, palm wax, silicon dioxide, microcrystalline cellulose-lactose and talc powder are mixed, the powder is directly compressed into a tablet. The obtained tablet is coated into a film-coated tablet by using a moisture-proof coating material (AMB). The powder direct compression technology is adopted, so that the technical complexity is greatly reduced, and the wet heat unit operation is avoided. The preparation process is simple, and the quality is stable.

Provided is a once-daily sustained-release tablet containing apixaban, the tablet comprising apixaban or a pharmaceutically acceptable salt thereof, polyethylene oxide as a sustained-release base and tocopherol polyethylene glycol succinate.

The invention relates to the technical field of pharmaceutical preparations, in particular to a preparation method of upatinib sustained release tablets based on fluidized bed granulation. The invention provides a method for preparing upatinib sustained release tablets by adopting a fluidized bed one-step granulation process. The method is suitable for upatinib semihydrate (C crystal form), anhydride (D crystal form) and amorphous raw materials. Through fluidized bed granulation, the main component upatinib is irregularly and uniformly dispersed in the auxiliary materials, the problems of mixing uniformity and content uniformity of the low-proportion main component are solved, the concentration of the main component is diluted by optimizing the adding sequence of the auxiliary materials, and the contact risk of upatinib and tartaric acid is reduced, so that the compatibility problem of upatinib and tartaric acid is solved.

The invention discloses a silybum marianum lipidosome applied to a liver protection tablet product and a preparation method, the silybum marianum lipidosome comprises a core material, and an internal wall material and an external wall material which sequentially wrap the surface of the core material; the core material is a silybum marianum extract; the inner wall material is modified soybean phospholipid; the outer wall material is a combination of starch sodium octenylsuccinate and polyethylene glycol. A lipidosome membrane embedding technology is adopted, the silybum marianum extract and soybean modified phospholipid are mixed according to a certain proportion and emulsified into a membrane, phospholipid bimolecular membrane embedding is formed, and then high-molecular compounds including starch sodium octenylsuccinate and polyethylene glycol are used as external wall materials to further include the phospholipid compound of the silybum marianum extract. The prepared lipidosome can be uniformly dispersed in an aqueous solution, the angle of repose is less than or equal to 40 degrees, the fluidity and the tabletting effect are better, the lipidosome is prepared into a sustained-release tablet, the bioavailability of the lipidosome can be improved, and the application of the lipidosome in a liver protection factor system can be expanded.

The invention provides a tofacitinib citrate sustained-release tablet, which is composed of a sustained-release tablet core and a coating layer, the sustained-release tablet core is prepared by uniformly mixing a solid dispersion and pharmaceutically acceptable auxiliary materials and then tabletting, the tofacitinib citrate sustained release tablet is characterized in that the solid dispersion is prepared from tofacitinib citrate, acrylic resin E and isomaltitol by utilizing a solvent evaporation method, and the coating layer comprises polyvinylpyrrolidone and tert-butyl p-hydroxyanisole. The prepared tofacitinib citrate tablet core particles are high in density, good in flowability and good in compressibility; the prepared tofacitinib citrate sustained release tablet is stable in quality, simple and feasible in process and suitable for large-scale production.

The application belongs to the technical field of pharmaceutical preparations, and specifically provides a carbidopa levodopa sustained-release tablet, which contains carbidopa, levodopa, potassium hydrogen tartrate, a sustained-release material, a binder and a lubricant. The carbidopa in the sustained-release tablet has good stability and is not prone to oxidative degradation, thereby improving the drug efficacy of the carbidopa levodopa sustained-release tablet. In addition, the wet granulation technology is used in the application, the preparation process is simple, the cost is low, and the application is suitable for industrial production.

This invention relates to a compustin sustained-release tablet and its preparation method. The compustin sustained-release tablet comprises a tablet core and a film coating layer covering the tablet core; the components of the compustin sustained-release tablet, by weight percentage, are 94.5%~98.3% sustained-release tablet core and 1.7%~5.5% film coating layer; the tablet core, by weight percentage, comprises the following raw material components: 32%~53% active ingredient, 30%~50% sustained-release material, 10%~30% filler, 1%~3% gliding agent, and 0.2%~1% lubricant, wherein the active ingredient is compustin; the film coating layer comprises a film-forming agent, polyethylene glycol, and additives, wherein the mass ratio of the film-forming agent, polyethylene glycol, and additives is (2~6.4):1:(1.7~5.3). Compared with the prior art, the preparation process of this invention is simple, and the obtained compustin sustained-release tablets have good release rate, stability, and bioequivalence, and are easy to industrialize.

The invention provides a nerve soothing and sleep aiding dark tea traditional Chinese medicine composite composition and a preparation method thereof, and belongs to the technical field of medicinal tea. The preparation method comprises the following steps: fermenting dark green tea, adding degradation microspheres into fermentation liquor, stirring and degrading to obtain dark green tea ferment without alkaloid, uniformly mixing the dark green tea ferment with a traditional Chinese medicine composition extracted from spina date seed, poria cocos, polygala tenuifolia, liquorice, ginseng and prepared rehmannia root, lactose, microcrystalline cellulose, magnesium stearate, sodium carboxymethyl cellulose, hydroxy propyl cellulose and sodium alginate, granulating, and tabletting to obtain the dark green tea tablet. The nerve-soothing and sleep-aiding dark tea traditional Chinese medicine compound composition is prepared. The prepared dark green tea traditional Chinese medicine composite composition for soothing nerves and helping sleep is a product combining low caffeine and high aroma and the slow-release tablets for soothing nerves and helping sleep, the utilization rate of dark green tea resources is increased, good effects of soothing nerves and helping sleep are achieved, and economic benefits are remarkable.

The utility model discloses a kind of trazodone hydrochloride sustained-release tablets release rate rapid detection equipment, it is related to pharmaceutical detection technical field, including installation box, the installation box outside is fixedly connected with observation window, the installation box inside is fixedly connected with baffle, the installation box inside is provided with two detection barrels, the detection barrel top is provided with cover plate, the cover plate top is fixedly connected with handle, the cover plate top is provided with notched, the installation box top is provided with automatic sampling mechanism, and one of the detection barrel bottom is provided with analog motion mechanism. The utility model discloses a kind of trazodone hydrochloride sustained-release tablets release rate rapid detection equipment, by the design of analog motion mechanism, the motion state of sustained-release tablets in human body is simulated, so that detection result is more close to actual situation, and the reliability of detection is improved.